A new experimental cancer treatment in showing great promise in reducing tumors in lung cancer patients.
While still in the beginning stages of clinical trials, early reports show that the drug may be able to target the “switch” that turns a particular type of cancer on and off. Crizotinib, also known as PF-02341066 or 1066 is currently undergoing clinical trials in the treatment of several forms of cancer, including non-small cell lung carcinoma (NSCLC).
So far, results look promising. Clinical trials revealed that over half the patients taking Crizotinib saw their tumors shrink, or had some other major change in their cancer.
“For [cancer cells] to grow and multiply and spread to other parts of the body constantly require certain signals to be on, and this drug basically turns off the signal,” said Emory University Winship Cancer Institute oncologist Dr. Suresh S. Ramalingam.
Despite the promise, researchers warn that Crizotinib is still in the experimental phase and that the effects of the drug may only last a short time.
The University of Chicago Medical Center is one of the first hospitals to start testing Crizotinib. Researchers are still seeking lung cancer patients to take part in this trial.
Learn more about Crizotinib and University of Chicago Medical Center trials here.